Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: An analysis of patient reports to the University of California, San Diego (UCSD) statin effects study

Drug Safety

Volumn 32, Issue 8, 2009, Pages 649-661

  Golomb, Beatrice A ^a,b   Kwon, Edwin K ^a,c   Koperski, Sabrina ^a   Evans, Marcella A ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; UNITED STATES;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANTICHOLESTEREMIC AGENTS; DATA COLLECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MITOCHONDRIA; OXIDATIVE STRESS; RISK FACTORS; UBIQUINONE; VITAMINS;

EID: 67650456301     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-200932080-00004     Document Type: Article

References (122)

1. Strong M, Rosenfeld J. Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4 (3): 136-43
2. Golomb BA. Patient targeted adverse event surveillance: use for hypothesis generation. Robert Wood Johnson Generalist Physician Faculty Scholar meeting. 2005 Nov 10; Ft Lauderdale (FL) [online]. Available from URL: https://www.statineffects.com/abstracts/RWJposter2005. pdf [Accessed 2009 Jan 27]
3. Golomb BA. Enhancing post-marketing drug surveillance: a response to expressed needs of patients. Robert Wood Johnson Generalist Physician Faculty Scholar meeting. 2006 Dec 1; San Antonio (TX) [online]. Available from URL: https://www.statineffects.com/abstracts/RWJabstract 2006.pdf [Accessed 2009 Jan 27]
4. Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosislike syndrome: an analysis of individual case safety reports from vigibase. Drug Saf 2007; 30 (6): 515-25
5. Buajordet I, Madsen S, Olsen H. Statins: the pattern of adverse effects with emphasis on mental reactions: data from a national and an international database [in Norwegian]. Tidsskrift for den Norske Laegeforening 1997; 117 (22): 3210-3
6. Halkin A, Lossos IS, Mevorach D. HMG-CoA reductase inhibitor-induced impotence [letter]. Ann Pharmacother 1996; 30 (2): 190
7. Boyd IW. Comment: HMG-CoA reductase inhibitorinduced impotence [letter; comment]. Ann Pharmacother 1996; 30 (10): 1199
8. Jackson G. Simvastatin and impotence [editorial]. BMJ 1997; 315: 31
9. Bruckert E, Giral P, Heshmati HM, et al. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther 1996; 21: 89-94
10. Adverse Drug Reactions Advisory Committee. Simvastatin and adverse endocrine effects in men. Aust Adv Drug React Bull 1995; 14 (3): 10
11. Halkin A, Lossos IS, Mevorach D. HMG-CoA reductase inhibitor-induced impotence [letter]. Ann Pharmacother 1996; 30 (2): 192
12. Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 2002; 19 (1): 95-8
13. Pia Iglesias G, Fernandez Fernandez FJ, Ameneiros Lago E, et al. HMG-CoA reductase inhibitors and sexual dysfunction [letter; in Spanish]. Ann Med Interna 2001; 18 (3): 171
14. Carvajal A, Macias D, Sainz M, et al. HMG CoA Reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems. Drug Saf 2006; 29 (2): 143-9
15. Boyd IW. Comment: HMG-CoA reductase inhibitorinduced impotence [letter]. Ann Pharmacother 1996; 30 (10): 1199
16. Halkin A, Lossos IS, Mevorach D. HMG-CoA reductase inhibitor-induced impotence [letter]. Ann Pharmacother 1996; 30 (2): 192
17. Solomon H, Samarasinghe YP, Feher MD, et al. Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract 2006; 60 (2): 141-5
18. Blanker MH, Verhagen AP. Lipid-lowering drugs and erectile dysfunction [letter]. Fam Pract 2002; 19 (5): 567
19. de Graaf L, Brouwers AH, Diemont WL. Is decreased libido associated with the use of HMG-CoA-reductase inhibitors? Br J Clin Pharmacol 2004; 58 (3): 326-8
20. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137 (7): 581-5
21. Evans MA, Golomb BA. Statin associated cognitive problems reportedby 171 subjects. Pharmacotherapy. In press
22. Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004; 117 (11): 823-9
23. Wagstaff LR, Mitton MW, Arvik BM, et al. Statinassociated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003; 23 (7): 871-80
24. Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological wellbeing. Am J Med 2000; 108 (7): 538-46
25. Jeppesen U, Gaist D, Smith T, et al. Statins and peripheral neuropathy. Eur J Clin Pharmacol 1999; 54 (11): 835-8
26. Adverse Drug Reactions Advisory Committee (ADRAC). Statins and peripheral neuropathy. Aust Adverse Drug Reactions Bull 2005; 24 (2): 6
27. Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy: a case-control study. Neurology 2002; 58 (9): 1333-7
28. Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004; 61 (6): 889-92
29. Mortensen SA, Leth A, Agner E, et al. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997; 18 Suppl.: S137-44
30. Di Giovanni S, Mirabella M, Spinazzola A, et al. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology 2001; 57 (3): 515-8
31. Beal MF. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radic Res 2002; 36 (4): 455-60
32. Levy G, Kaufmann P, Buchsbaum R, et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 2006; 66 (5): 660-3
33. Praline J, Guennoc AM, Limousin N, et al. ALS and mercury intoxication: a relationship? Clin Neurol Neurosurg 2007; 109 (10): 880-3
34. Morahan JM, Yu B, Trent RJ, et al. Genetic susceptibility to environmental toxicants in ALS. Am J Med Genet B Neuropsychiatr Genet 2007; 144 (7): 885-90
35. O'Neill MJ, Murray TK, Lakics V, et al. The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr Drug Targets CNS Neurol Disord 2002; 1 (4): 399-411
36. Abel EL. Football increases the risk for Lou Gehrig's disease, amyotrophic lateral sclerosis. Percept Mot Skills 2007; 104 (3 Pt 2): 1251-4
37. Chio A, Benzi G, Dossena M, et al. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain 2005; 128 (Pt 3): 472-6
38. Wicks P, Ganesalingham J, Collin C, et al. Three soccer playing friends with simultaneous amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2007; 8 (3): 177-9
39. Vanacore N, Binazzi A, Bottazzi M, et al. Amyotrophic lateral sclerosis in an Italian professional soccer player. Parkinsonism Relat Disord 2006; 12 (5): 327-9
40. Belli S, Vanacore N. Proportionate mortality of Italian soccer players: is amyotrophic lateral sclerosis an occupational disease? Eur J Epidemiol 2005; 20 (3): 237-42
41. Taioli E. All causes mortality in male professional soccer players. Eur J Public Health 2007; 17 (6): 600-4
42. Konagaya M, Kato T, Sakai M, et al. A clinical and pathological study of a Japanese case of amyotrophic lateral sclerosis/parkinsonism-dementia complex with family history. J Neurol 2003; 250 (2): 164-70
43. Plato CC, Garruto RM, Galasko D, et al. Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: changing incidence rates during the past 60 years. Am J Epidemiol 2003; 157 (2): 149-57
44. Plato CC, Galasko D, Garruto RM, et al. ALS and PDC of Guam: forty-year follow-up. Neurology 2002; 58 (5): 765-73
45. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther 2005; 19 (6): 403-14
46. Scott RS, Lintott CJ, Wilson MJ. Simvastatin and side effects. N Z Med J 1991; 104 (924): 493-5
47. Colman E, Szarfman A, Wyeth J, et al. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system. Pharmacoepidemiol Drug Saf 2008; 17 (11): 1068-76
48. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008; 8 (6): 373-418
49. McClure DL, Valuck RJ, Glanz M, et al. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 2007; 16 (2): 132-43
50. Karlsson J, Diamant B, Edlund PO, et al. Plasma ubiquinone, alpha-tocopherol and cholesterol in man. Int J Vitam Nutr Res 1992; 62 (2): 160-4
51. Neuhouser ML, Rock CL, Eldridge AL, et al. Serum concentrations of retinol, alpha-tocopherol and the carotenoids are influenced by diet, race and obesity in a sample of healthy adolescents. J Nutr 2001; 131 (8): 2184-91
52. Karlsson J, Diamant B, Theorell H, et al. Ubiquinone and alpha-tocopherol in plasma; means of translocation or depot. Clin Investig 1993; 71 (8 Suppl.): S84-91
53. Oranje WA, Sels JP, Rondas-Colbers GJ, et al. Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients. Clin Chim Acta 2001; 311 (2): 91-4
54. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004; 3 (3): 205-14
55. Huang X, Chen H, Miller WC, et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord 2006; 22 (3): 377-81
56. de Lau LM, Koudstaal PJ, Hofman A, et al. Serum cholesterol levels and the risk of Parkinson's disease. Am J Epidemiol 2006; 164 (10): 998-1002
57. Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 2008; 70 (13): 1004-9
58. Zager RA, Johnson AC, Hanson SY. Proximal tubular cholesterol loading after mitochondrial, but not glycolytic, blockade. Am J Physiol Renal Physiol 2003; 285 (6): F1092-9
59. Berthold HK, Naini A, Di Mauro S, et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf 2006; 29 (8): 703-12
60. Albano CB, Muralikrishnan D, Ebadi M. Distribution of coenzyme Q homologues in brain. Neurochem Res 2002; 27 (5): 359-68
61. Lenaz G, D'Aurelio M, Merlo Pich M, et al. Mitochondrial bioenergetics in aging. Biochim Biophys Acta 2000; 1459 (2-3): 397-404
62. Sastre J, Pallardo FV, Vina J. The role of mitochondrial oxidative stress in aging. Free Radic Biol Med 2003; 35 (1): 1-8
63. Linnane AW, Zhang C, Yarovaya N, et al. Human aging and global function of coenzyme Q10. Ann N Y Acad Sci 2002; 959: 396-411
64. Whitman GJ, Niibori K, Yokoyama H, et al. The mechanisms of coenzyme Q10 as therapy for myocardial ischemia reperfusion injury. Mol Aspects Med 1997; 18 Suppl.: S195-203
65. Fernandez-Ayala DJ, Martin SF, Barroso MP, et al. Coenzyme Q protects cells against serum withdrawalinduced apoptosis by inhibition of ceramide release and caspase-3 activation. Antioxid Redox Signal 2000; 2 (2): 263-75
66. Kagan T, Davis C, Lin L, et al. Coenzyme Q10 can in some circumstances block apoptosis, and this effect is mediated through mitochondria. AnnN Y Acad Sci 1999; 887: 31-47
67. Lopez-Lluch G, Barroso MP, Martin SF, et al. Role of plasma membrane coenzyme Q on the regulation of apoptosis. Biofactors 1999; 9 (2-4): 171-7
68. Papucci L, Schiavone N, Witort E, et al. Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J Biol Chem 2003; 278 (30): 28220-8
69. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002; 59 (10): 1541-50
70. Barbiroli B,Frassineti C, Martinelli P, et al. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies: an in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cell Mol Biol (Noisy-le-grand) 1997; 43 (5): 741-9
71. Mahoney DJ, Parise G, Tarnopolsky MA. Nutritional and exercise-based therapies in the treatment of mitochondrial disease. Curr Opin Clin Nutr Metab Care 2002;5 (6): 619-29
72. Rosenfeldt FL, Pepe S, Linnane A, et al. Coenzyme Q10 protects the aging heart against stress: studies in rats, human tissues, and patients. Ann N Y Acad Sci 2002; 959: 355-9
73. Mandavilli BS, Santos JH, Van Houten B. Mitochondrial DNA: repair and aging. Mutat Res 2002; 509 (1-2): 127-51
74. Lee HC, Wei YH. Mutation and oxidative damage of mitochondrial DNA and defective turnover of mitochondria in human aging. J Formos Med Assoc 1997; 96 (10): 770-8
75. Genova ML, Pich MM, Bernacchia A, et al. The mitochondrial production of reactive oxygen species in relation to aging and pathology. Ann N Y Acad Sci 2004; 1011: 86-100
76. Lestienne P. Do mitochondria play a role in aging? C R Seances Soc Biol Fil 1997; 191 (4): 579-92
77. Vladutiu G. Statin-induced adverse effects and malignant hyperthermia susceptibility: comment on the article by Guis et al. Arthritis Rheum 2007; 57 (1): 186-17
78. Oh J, Ban MR, Miskie BA, et al. Genetic determinants of statin intolerance. Lipids Health Dis 2007; 6: 7
79. Sinzinger H, Lupattelli G, Chehne F. Increased lipid peroxidation in a patient with CK-elevation and muscle pain during statin therapy. Atherosclerosis 2000; 153 (1): 255-6
80. Sinzinger H, Lupattelli G, Chehne F, et al. Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Coenzyme-A-reductase inhibitor therapy. J Clin Pharm Ther 2001; 26 (4): 303-10
81. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006; 34 (2): 153-62
82. Gambelli S, Dotti MT, Malandrini A, et al. Mitochondrial alterations in muscle biopsies of patients on statin therapy. J Submicrosc Cytol Pathol 2004; 36 (1): 85-9
83. Meyer RA, Slade JM, Towse TF, et al. Elevated muscle phosphodiesterase in 31P-NMR spectra of patients on statins [abstract]. Proc Intl Soc Mag Reson Med 2005; 13: 2036
84. Schick BA, Laaksonen R, Frohlich JJ, et al. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther 2007; 81 (5): 650-3
85. Guis S, Figarella-Branger D, Mattei JP, et al. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis Rheum 2006; 55 (4): 551-7
86. Phillips PS, Phillips CT, Sullivan MJ, et al. Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis 2004; 177 (1): 183-8
87. Paiva H, Thelen KM, Van Coster R, et al. High-dosestatins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005; 78 (1): 60-8
88. De Pinieux G, Chariot P, Ammi-Said M, et al. Lipidlowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996; 42 (3): 333-7
89. Chariot P, Abadia R, Agnus D, et al. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med 1993; 94 (1): 109-10
90. Thomas JE, Lee N, Thompson PD. Statins provoking MELAS syndrome: a case report. Eur Neurol 2007; 57 (4): 232-5
91. Neale R, Reynolds TM, Saweirs W. Statin precipitated lactic acidosis? J Clin Pathol 2004; 57 (9): 989-90
92. Goli AK, Goli SA, Byrd Jr RP, et al. Simvastatin-induced lactic acidosis: a rare adverse reaction? Clin Pharmacol Ther 2002; 72 (4): 461-4
93. England JD, Walsh JC, Stewart P, et al. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors: simvastatin and pravastatin [letter]. Aust N Z J Med 1995; 25 (4): 374-5
94. Diaczok BJ, Shali R. Statins unmasking a mitochondrial myopathy: a case report and proposed mechanism of disease. South Med J 2003; 96 (3): 318-20
95. Troseid M, Henriksen OA, Lindal S. Statin-associated myopathy with normal creatine kinase levels: case report from a Norwegian family. APMIS 2005; 113 (9): 635-7
96. Fukada K, Zhang F, Vien A, et al. Mitochondrial proteomic analysis of a cell line model of familial amyotrophic lateral sclerosis. Mol Cell Proteomics 2004; 3 (12): 1211-23
97. Mancuso M, Conforti FL, Rocchi A, et al. Could mitochondrial haplogroups play a role in sporadic amyotrophic lateral sclerosis? Neurosci Lett 2004; 371 (2-3): 158-62
98. Xu Z, Jung C, Higgins C, et al. Mitochondrial degeneration in amyotrophic lateral sclerosis. J Bioenerg Biomembr 2004; 36 (4): 395-9
99. Dupuis L, Di Scala F, Rene F, et al. Up-regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis. Faseb J 2003; 17 (14): 2091-3
100. Dupuis L, Gonzalez de Aguilar JL, Oudart H, et al. Mitochondria in amyotrophic lateral sclerosis: a trigger and a target. Neurodegener Dis 2004; 1 (6): 245-54
101. Wallace DC. A mitochondrial paradigm for degenerative diseases and ageing. Novartis Found Symp 2001; 235: 247-63; discussion 263-6
102. Corral-Debrinski M, Horton T, Lott MT, et al. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics 1994; 23 (2): 471-6
103. Wallace DC. Mitochondrial defects in neurodegenerative disease. Ment Retard Dev Disabil Res Rev 2001; 7 (3): 158-66
104. Borthwick GM, Johnson MA, Ince PG, et al. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann Neurol 1999; 46 (5): 787-90
105. Dupuis L, Gonzalez de Aguilar JL, Echaniz-Laguna A, et al. Mitochondrial dysfunction in amyotrophic lateral sclerosis also affects skeletal muscle. Muscle Nerve 2006; 34 (2): 253-4
106. Kew JJ, Leigh PN, Playford ED, et al. Cortical function in amyotrophic lateral sclerosis: a positron emission tomography study. Brain 1993; 116 (Pt 3): 655-80
107. Sinzinger H, Chehne F, Lupattelli G. Oxidation injury in patients receiving HMG-CoA reductase inhibitors: occurrence in patients without enzyme elevation or myopathy. Drug Saf 2002; 25 (12): 877-83
108. Food and Drug Administration. FDA Public Health Advisory on Crestor (rosuvastatin) [online]. Available from URL: http://www.fda.gov/cder/drug/ advisory/crestor-3-2005.htm [Accessed 2005 Mar 2]
109. McDermott MM, Guralnik JM, Greenland P, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003; 107 (5): 757-61
110. Fisher S, Bryant SG. Postmarketing surveillance: accuracy of patient drug attribution judgments. Clin Pharmacol Ther 1990; 48 (1): 102-7
111. Fisher S, Bryant SG, Kent TA, et al. Patient drug attributions and postmarketing surveillance. Pharmacotherapy 1994; 14 (2): 202-9
112. Fisher S, Bryant SG, Kluge RM. New approaches to postmarketing surveillance. Psychopharmacology (Berl) 1986; 90 (3): 347-50
113. Fisher S, Bryant SG. Postmarketing surveillance of adverse drug reactions: patient self-monitoring. J Am Board Fam Pract 1992; 5 (1): 17-25
114. Jarernsiripornkul N, Krska J, Richards RM, et al. Patient reporting of adverse drug reactions: useful information for pain management? Eur J Pain 2003; 7 (3): 219-24
115. Gray GC, Reed RJ, Kaiser KS, et al. Self-reported symptoms and medical conditions among 11,868 Gulf War-era veterans: the Seabee Health Study. Am J Epidemiol 2002; 155 (11): 1033-44
116. Kural BV, Orem C, Uydu HA, et al. The effects of lipidlowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia. Coron Artery Dis 2004; 15 (5): 277-83
117. Harangi M, Seres I, Varga Z, et al. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur J Clin Pharmacol 2004; 60 (10): 685-91
118. Tomas M, Senti M, Garcia-Faria F, et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2000; 20 (9): 2113-9
119. Deakin S, Guernier S, James RW. Pharmacogenetic interaction between paraoxonase-1 gene promoter polymorphism C-107T and statin. Pharmacogenet Genomics 2007; 17 (6): 451-7
120. Beltowski J, Wojcicka G, Jamroz A. Differential effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on plasma paraoxonase 1 activity in the rat. Pol J Pharmacol 2002; 54 (6): 661-71
121. Gouedard C, Koum-Besson N, Barouki R, et al. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol 2003; 63 (4): 945-56
122. Muller T, Kuhn W, Pohlau D, et al. Parkinsonism unmasked by lovastatin. Ann Neurol 1995; 37 (5): 685-6